Modest Association Between C-reactive Protein, Breast Cancer Risk
the Cancer Therapy Advisor take:
Higher levels of C-reactive protein (CRP), a nonspecific marker of inflammation, were suggestive of an association with increased breast cancer risk, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
In this study, 943 cases from the Nurses’ Health Study (NHS) and 1,919 cases from the Women’s Health Study (WHS) were evaluated.
Results showed higher CRP levels were associated with a greater risk of breast cancer for those in the NHS (quintile 5 vs. 1: RR, 1.27; 95% CI: 0.93, 1.73; P trend = 0.02). However, no correlation between CRP levels and breast cancer risk were observed in the WHS (quintile 5 vs. 1: RR, 0.89; 95% CI: 0.76, 1.06; P trend = 0.38).
The random effect meta-analysis conducted on the data showed a slightly increased risk in women with the highest versus lowest levels of CRP (RR, 1.26; 95% CI: 1.07, 1.49).
Higher levels of C-reactive protein were suggestive of an association with increased breast cancer risk.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed